Skip to content
+49 40 3009799 0 order@oncoscience.de
EnglishEnglish
  • DeutschDeutsch
Oncoscience
  • COMPANY
  • ONCOLOGY
  • PRODUCT
  • RESEARCHExpand
    • CLINICAL TRIALS
    • PUBLICATIONS
  • FAQ
  • NEWS
+49 40 3009799 0 
EnglishEnglish
  • DeutschDeutsch
Oncoscience
NEWS

Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancer

ByOncoscience 12. September 2007

Read More Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancerContinue

Oncoscience GmbH
Osterbrooksweg 59
22869 Schenefeld
Germany

 

Phone: +49-40 300 9799-0
Fax: +49-40 300 9799-20
Email: order@oncoscience.de

part of

Legal Notice

© 2025 Oncoscience

Scroll to top
  • COMPANY
  • ONCOLOGY
  • PRODUCT
  • RESEARCH
    • CLINICAL TRIALS
    • PUBLICATIONS
  • FAQ
  • NEWS
Search
Diese Website benutzt Cookies. Wenn du die Website weiter nutzt, gehen wir von deinem Einverständnis aus.OKDatenschutzerklärung